prulifloxacin has been researched along with ulifloxacin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (39.13) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kazuno, K; Kise, M; Kitano, M; Matsuda, M; Matsuoka, M; Ozaki, M; Segawa, J; Shirahase, I; Tomii, Y | 1 |
| Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y | 1 |
| Mitsuhashi, S; Yoshida, T | 1 |
| Nakamura, T; Nakasuji, T; Sakai, K; Shindo, Y; Sumi, N; Tateda, C; Yamakawa, S | 1 |
| Ando, M; Iwakura, K; Kojima, M; Shindo, Y; Sumi, N; Tamura, H; Watanabe, M; Yamashita, Y | 1 |
| Ishibashi, S; Iwakura, K; Kakemi, K; Kawaminami, A; Matsuyama, S; Oka, T; Shindo, Y; Sumi, N; Tawaratani, T | 1 |
| Ishikawa, Y; Iwakura, K; Nishiguchi, Y; Shimazu, H; Shindo, Y; Sumi, N; Yoshida, M | 1 |
| Fukuda, K; Iwakura, K; Nishimura, N; Shindo, Y; Sumi, N; Tamura, K; Yamazaki, S | 1 |
| Ide, M; Iwakura, K; Nagatani, M; Oda, S; Shindo, Y; Sumi, N; Tamura, K | 1 |
| Eda, T; Hosaka, M; Hoshino, K; Inoue, M; Kaieda, S; Kitasato, H; Kuga, A; Okamoto, R; Sato, Y; Seto, I | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Keam, SJ; Perry, CM | 1 |
| Cochetti, I; Ferrante, L; Montanari, MP; Rossi, V; Tili, E; Varaldo, PE | 1 |
| Allegranzi, B; Ciottoli, GB; Concia, E; Dionisio, P; Marchetti, M; Orticelli, G | 1 |
| Aoki, M; Iguchi, M; Kato, Y; Kurosawa, T; Shibasaki, S; Tsuji, A; Yagi, Y | 1 |
| Cagini, C; Pellegrino, RM; Segoloni, F | 1 |
| Fan, G; Li, Z; Pan, Y; Wen, J; Wu, Y; Zhang, L | 1 |
| Choudhury, H; Das, A; Das, AK; Pal, TK; Roy, B | 1 |
| Das, AK; Nandi, U; Pal, TK; Roy, B | 1 |
| Carlucci, G; Cifelli, R; Locatelli, M; Romagnoli, A | 1 |
| Ammendola, M; Comandini, A; Coppola, P; Del Vecchio, A; Di Loreto, G; Garofolo, F; Picollo, R; Tellone, V; Tongiani, S | 1 |
3 trial(s) available for prulifloxacin and ulifloxacin
| Article | Year |
|---|---|
Prulifloxacin.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Bronchitis, Chronic; Ciprofloxacin; Clavulanic Acid; Dioxolanes; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Half-Life; Humans; Italy; Molecular Structure; New Zealand; Pefloxacin; Piperazines; Prodrugs; Quinolones; Urinary Tract Infections | 2004 |
Penetration of orally administered prulifloxacin into human lung tissue.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Dioxolanes; Female; Fluoroquinolones; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Piperazines; Pneumonectomy; Quinolones | 2005 |
New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Dioxolanes; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Renal Insufficiency; Young Adult | 2018 |
20 other study(ies) available for prulifloxacin and ulifloxacin
| Article | Year |
|---|---|
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Carboxylic Acids; Escherichia coli Infections; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Pseudomonas Infections; Quinolones; Structure-Activity Relationship | 1992 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluation, Preclinical; Enoxacin; Female; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Prodrugs; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Urinary Tract Infections | 1991 |
Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Dioxolanes; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Topoisomerase II Inhibitors | 1993 |
[Antigenicity studies of prulifloxacin (NM441)].
Topics: Anaphylaxis; Animals; Anti-Infective Agents; Antigens; Dioxolanes; Female; Fluoroquinolones; Freund's Adjuvant; Guinea Pigs; Male; Mice; Mice, Inbred C57BL; Passive Cutaneous Anaphylaxis; Piperazines; Quinolones; Rats; Serum Albumin; Serum Albumin, Bovine | 1996 |
[Mutagenicity studies of prulifloxacin (NM441) and the active metabolite (NM394)].
Topics: Animals; Anti-Infective Agents; Chromosome Aberrations; Cricetinae; Dioxolanes; Escherichia coli; Fluoroquinolones; Humans; Male; Mice; Mice, Inbred Strains; Micronucleus Tests; Mutagenicity Tests; Piperazines; Quinolones; Salmonella typhimurium | 1996 |
[Renal toxicity of prulifloxacin (NM441) in rats].
Topics: Administration, Oral; Animals; Anti-Infective Agents; Crystallization; Dioxolanes; Female; Fluoroquinolones; Kidney; Kidney Tubular Necrosis, Acute; Kidney Tubules; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley | 1996 |
[Single-dose toxicity studies of prulifloxacin (NM441) in mice, rats and dogs and the active metabolite (NM394) in rats].
Topics: Administration, Oral; Animals; Anti-Infective Agents; Dioxolanes; Dogs; Female; Fluoroquinolones; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Lethal Dose 50; Male; Mice; Mice, Inbred Strains; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley | 1996 |
[A 4-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test].
Topics: Administration, Oral; Animals; Anti-Infective Agents; Cecum; Chlorides; Dioxolanes; Drinking; Eating; Female; Fluoroquinolones; gamma-Globulins; Kidney Tubular Necrosis, Acute; Male; Organ Size; Piperazines; Potassium; Quinolones; Rats; Rats, Sprague-Dawley; Weight Gain | 1996 |
[A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test].
Topics: Administration, Oral; Alanine Transaminase; Alpha-Globulins; Animals; Anti-Infective Agents; Cartilage, Articular; Dioxolanes; Dogs; Dyskinesia, Drug-Induced; Female; Fluoroquinolones; Kidney; Leukocyte Count; Male; Piperazines; Quinolones | 1996 |
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Quinolones; Respiratory Tract Infections; Sepsis | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin.
Topics: Colony Count, Microbial; Culture Media, Conditioned; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Biological Transport; Biotransformation; Carrier Proteins; Dioxolanes; Fluoroquinolones; Hepatocytes; Injections, Intravenous; Liver; Male; Membrane Transport Modulators; Metabolic Clearance Rate; Models, Biological; Piperazines; Prodrugs; Quinolones; Rats; Rats, Sprague-Dawley | 2007 |
Simultaneous determination of Ciprofloxacin and the active metabolite of Prulifloxacin in aqueous human humor by high-performance liquid chromatography.
Topics: Aged; Aged, 80 and over; Aqueous Humor; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Dioxolanes; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Reproducibility of Results | 2008 |
Determination of ulifloxacin, the active metabolite of prulifloxacin, in human plasma by a 96-well format solid-phase extraction and capillary zone electrophoresis.
Topics: Anti-Bacterial Agents; Dioxolanes; Electrophoresis, Capillary; Fluoroquinolones; Humans; Piperazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2008 |
Development and validation of a liquid chromatography-tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: application to toxicokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Dioxolanes; Drug Stability; Fluoroquinolones; Linear Models; Male; Piperazines; Rabbits; Rats; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2011 |
Correlation among the toxicity profiling (28-days repeated oral dose toxicity), toxicokinetics and tissue distribution data of ulifloxacin, the active metabolite of prulifloxacin in Wistar albino rats.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Arthritis; Dermatitis, Phototoxic; Dioxolanes; Female; Fluoroquinolones; Gastric Mucosa; Liver; Lung; Male; Piperazines; Rats; Rats, Wistar; Stomach; Synovial Fluid; Tissue Distribution; Toxicity Tests, Subacute | 2012 |
Stability study of Prulifloxacin and Ulifloxacin in human plasma by HPLC-DAD.
Topics: Chromatography, High Pressure Liquid; Dioxolanes; Drug Stability; Fluoroquinolones; Humans; Molecular Structure; Piperazines; Solid Phase Extraction; Topoisomerase II Inhibitors | 2016 |